• metastatic/advanced OC (mOC) - maintenance (M) 1
• pancreatic ductal adenocarcinoma
• PIK3CA-related overgrowth spectrum
• prostate cancer (PC)

 

• endocrine therapy
• androgen deprivation therapy (ADT)
• abiraterone plus ADT
• abiraterone plus docetaxel plus ADT
• apalutamide plus ADT
• darolutamide plus doxetaxel plus ADT
• docetaxel plus ADT
• enzalutamide
• enzalutamide plus ADT
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• anti-PD-(L)1
• pembrolizumab based treatment

• versus all
• vs chemotherapy
• vs endocrine therapy
• vs androgen deprivation therapy (ADT)
• vs docetaxel plus ADT
• vs non active control
• vs placebo

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

prostate cancer (PC), endocrine therapy vs. docetaxel plus ADT, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;